CStone Pharmaceuticals
HKEX:2616
Intrinsic Value
Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. [ Read More ]
The intrinsic value of one
CStone Pharmaceuticals
stock under the Base Case scenario is
4.77
HKD.
Compared to the current market price of 0.9 HKD,
CStone Pharmaceuticals
is
Undervalued by 81%.
CStone Pharmaceuticals's market capitalization is 1.2B HKD.
CStone Pharmaceuticals stock price is 0.9 HKD.
CStone Pharmaceuticals stock price (0.9 HKD) is 81% less than its Intrinsic Value (4.77 HKD).
CStone Pharmaceuticals. Open DCF Valuation
CStone Pharmaceuticals stock price (0.9 HKD) is 81% less than its Relative Value (4.77 HKD). Open Relative Valuation
CStone Pharmaceuticals has upside potential of 527% compared to the average analyst price target.
Open Wall St Estimates
CStone Pharmaceuticals's Revenue has dropped by 4% over the past 12 months.
CStone Pharmaceuticals's short-term assets (1B CNY) exceed its short-term liabilties (803m CNY).
CStone Pharmaceuticals's long-term assets (2B CNY) exceed its long-term liabilties (1B CNY).
CStone Pharmaceuticals's Revenue is forecast to grow at a rate of 25% per year over the next 3 years.
CStone Pharmaceuticals's ROE (Return on Equity) has significantly decreased in the last 3 years from -45% to -70%, and is approaching profitability.
CStone Pharmaceuticals's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -411% to -166%, and is approaching profitability.
CStone Pharmaceuticals has negative Operating Income for the last twelve months.
CStone Pharmaceuticals has negative Net Income for the last twelve months.
CStone Pharmaceuticals's ROE (Return on Equity) for the past 12 months is negative and is equal to -70%.
CStone Pharmaceuticals's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -166%.
CStone Pharmaceuticals's Revenue has been falling by 24% per year for the last 3 years.
CStone Pharmaceuticals has positive Gross Profit for the last twelve months.
CStone Pharmaceuticals's D/E (Debt to Equity) is very low and is equal to 0.29.
CStone Pharmaceuticals has negative Free Cash Flow for the last twelve months.
CStone Pharmaceuticals has negative three-year average ROE (Return on Equity): -81%. The company is not efficient at transforming stockholders' equity into net income.
CStone Pharmaceuticals has negative three-year average ROIC (Return on Invested Capital): -284%. The company is not efficient at using invested capital to generate operating income.
CStone Pharmaceuticals has negative Net Debt. This means that the company has more cash and short-term investments (1B CNY) than debt (178m CNY).
CStone Pharmaceuticals's Altman Z-Score is very low and is equal to -6.48.
CStone Pharmaceuticals doesn't generate enough operating income (-508m CNY) to safely cover interest payments on its debt (11m CNY).
Valuation Backtest
CStone Pharmaceuticals
Run backtest to discover the historical profit from buying and selling
CStone Pharmaceuticals
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
CStone Pharmaceuticals
Balance Sheet Decomposition
CStone Pharmaceuticals
| Current Assets | 1.2B |
| Cash & Short-Term Investments | 1B |
| Receivables | 185.9m |
| Other Current Assets | 43m |
| Non-Current Assets | 425.5m |
| Long-Term Investments | 3.6m |
| PP&E | 179.4m |
| Intangibles | 217.5m |
| Other Non-Current Assets | 25m |
| Current Liabilities | 803.1m |
| Accounts Payable | 346.9m |
| Accrued Liabilities | 265.9m |
| Other Current Liabilities | 190.3m |
| Non-Current Liabilities | 252.9m |
| Long-Term Debt | 177.7m |
| Other Non-Current Liabilities | 75.2m |
Earnings Waterfall
CStone Pharmaceuticals
|
Revenue
|
463.8m
CNY
|
|
Cost of Revenue
|
-159.5m
CNY
|
|
Gross Profit
|
304.3m
CNY
|
|
Operating Expenses
|
-812.5m
CNY
|
|
Operating Income
|
-508.2m
CNY
|
|
Other Expenses
|
141m
CNY
|
|
Net Income
|
-367.2m
CNY
|
Free Cash Flow Analysis
CStone Pharmaceuticals
Profitability Score
Profitability Due Diligence
CStone Pharmaceuticals's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
CStone Pharmaceuticals's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
CStone Pharmaceuticals's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
CStone Pharmaceuticals's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
CStone Pharmaceuticals
According to Wall Street analysts, the average 1-year price target for
CStone Pharmaceuticals
is 5.65 HKD
with a low forecast of 3.31 HKD and a high forecast of 7.94 HKD.
Shareholder Return
Price
CStone Pharmaceuticals
| Average Annual Return | -21.77% |
| Standard Deviation of Annual Returns | 16.57% |
| Max Drawdown | -95% |
| Market Capitalization | 1.2B HKD |
| Shares Outstanding | 1 274 052 442 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
CStone Pharmaceuticals
Country
Industry
Market Cap
Dividend Yield
Description
Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 264 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The firm conducts its businesses mainly in domestic market.
Contact
IPO
Employees
Officers
The intrinsic value of one
CStone Pharmaceuticals
stock under the Base Case scenario is
4.77
HKD.
Compared to the current market price of 0.9 HKD,
CStone Pharmaceuticals
is
Undervalued by 81%.
You don't have any saved screeners yet
